Free biotech stocks directory, pharma stocks, telemedicine stocks ...
Zynerba Pharmaceuticals To Present At The H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference being held June 26, 2023.
Investors interested in arranging a virtual meeting with the Company's management during the conference should contact the H.C. Wainwright conference coordinator. A webcast of the presentation will be available on-demand here and under the Events & Webcasts tab of the Investors section of the Zynerba website at www.Zynerba.Com beginning June 26, 2023 at 7:00 a.M. ET. An archived replay will be available on the Company's website following the event for 60 days.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome and 22q11.2 deletion syndrome. Learn more at www.Zynerba.Com and follow us on Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the Company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, incentive and other tax credit eligibility, collectability and timing, and availability of and the need for additional financing; the Company's ability to obtain additional funding to support its clinical development programs; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; clinical results for the Company's product candidates may not be replicated or continue to occur in additional trials and may not otherwise support further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration, the European Medicines Agency and other foreign regulatory agencies may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company's ability to obtain and maintain regulatory approval for its product candidates, and the labeling under any such approval; the Company's reliance on third parties to assist in conducting pre-clinical and clinical trials for its product candidates; delays, interruptions or failures in the manufacture and supply of the Company's product candidates the Company's ability to commercialize its product candidates; the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates; the Company's expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates; the Company's ability to regain compliance with the requirements for continued listing on the Nasdaq Capital Market, including the risk of not obtaining stockholder approval for a potential reverse stock split; the extent to which health epidemics and other outbreaks of communicable diseases, including COVID-19, could disrupt our operations or adversely affect our business and financial conditions; and the extent to which inflation, banking stability or global instability, including political instability, may disrupt our business operations or our financial condition. This list is not exhaustive and these and other risks are described in the Company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.Sec.Gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Story continues
Zynerba Contacts
Peter VozzoICR WestwickeOffice: 443.213.0505Peter.Vozzo@Westwicke.Com
DNA Deletion And Duplication And The Associated Genetic Disorders
Amos-Landgraf, J. M., et al. Chromosome breakage in the Prader-Willi and Angelman syndromes involves recombination between large, transcribed repeats at proximal and distal breakpoints. American Journal of Human Genetics 65, 370–386 (1999)
Bailey, J. A., et al. Primate segmental duplications: Crucibles of evolution, diversity, and disease. Nature Reviews Genetics 7, 552–564 (2006) doi:10.1038/nrg1895 (link to article)
Brewer, C., et al. A chromosomal deletion map of human malformation. American Journal of Human Genetics 63, 1153–1159 (1998)
Chance, P. F., et al. Two autosomal dominant neuropathies result from reciprocal DNA duplication/deletion of a region on chromosome 17. Human Molecular Genetics 3, 223–228 (1994)
Chen, H. Cri du chat syndrome. EMedicine (2007) (link to article)
Chen, K. S., et al. Homologous recombination of a flanking repeat gene cluster is a mechanism for a common contiguous gene deletion syndrome. Nature Genetics 17, 154-163 (1997) doi:10.1038/ng1097-154 (link to article)
Christian, S. L., et al. Large genomic duplicons map to sites of instability in Prader-Willi/Angelman syndrome chromosome region (15q11-q13). Human Molecular Genetics 8, 1025–1037 (1999)
Clark, A. G. Hot spots unglued. Nature Genetics 37, 563–564 (2005) doi:10.1038/ng0605-563 (link to article)
Emanuel, B. S., & Shaikh, T. H. Segmental duplications: An "expanding" role in genomic instability and disease. Nature Reviews Genetics 2, 791–800 (2001) doi:10.1038/35093500 (link to article)
Hedrick, P. W. Inference of recombination hotspots using gametic disequilibrium values. Heredity 60, 435–438 (1988)
Jacobs, P. A., et al. Estimates of the frequency of chromosome abnormalities detectable in unselected newborns using moderate levels of banding. Journal of Medical Genetics 29, 103–108 (1992)
Jeffreys, A. J., et al. High-resolution mapping of crossovers in human sperm defines a minisatellite-associated recombination hotspot. Molecular Cell 2, 267–273 (1998)
Jeffreys, A. J., et al. High resolution analysis of haplotype diversity and meiotic crossover in the human TAP2 recombination hotspot. Human Molecular Genetics 9, 725–733 (2000)
Kauppi, A., et al. Where the crossovers are: Recombination distributions in mammals. Nature Reviews Genetics 5, 413–424 (2004) doi:10.1038/nrg1346 (link to article)
Kong, A. Et al. Recombination rate and reproductive success in humans. Nature Genetics 36, 1203–1206 (2004) doi:10.1038/ng1445 (link to article)
Lupski, J. R. Charcot-Marie-Tooth disease: Lessons in genetic mechanisms. Molecular Medicine 4, 3–11 (1998)
Lupski, J. R., & Stankiewicz, P. Genomic disorders: Molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genetics 1, 627–633 (2005)
Munns, C., & Glass, I. SHOX-related haploinsufficiency disorders. Gene Reviews (2008)
Perez-Jurado, L. A., et al. A duplicated gene in the breakpoint regions of the 7q11.23 Williams-Beuren syndrome deletion encodes the initiator binding protein TFII-I and BAP-135, a phosphorylation target of BTK. Human Molecular Genetics 7, 325–334 (1998)
Peoples, R., et al. A physical map, including a BAC/PAC clone contig, of the Williams-Beuren syndrome-deletion region at 7q11.23. American Journal of Human Genetics 66, 47–68 (2000)
Ptak, S. E., et al. Absence of the TAP2 human recombination hotspot in chimpanzees. PLoS Biology 2, 849–855 (2004)
Shaw, C. J., & Lupski, J. R. Implications of human genome architecture for rearrangement-based disorders: The genomic basis of disease. Human Molecular Genetics 13, R57–R64 (2004)
Stankiewicz, P., et al. Genome architecture catalyzes nonrecurrent chromosomal rearrangements. American Journal of Human Genetics 72, 1101–1116 (2003)
Chromosomal Abnormalities
Chromosomal abnormalities, alterations and aberrations are at the root of many inherited diseases and traits. Chromosomal abnormalities often give rise to birth defects and congenital conditions that may develop during an individual's lifetime. Examining the karyotype of chromosomes (karyotyping) in a sample of cells can allow detection of a chromosomal abnormality and counselling can then be offered to parents or families whose offspring are at risk of growing up with a genetic disorder.
Types of chromosomal abnormalityA chromosomal abnormality may be numerical or structural and examples are described below:
Numerical abnormalitiesThe normal human chromosome contains 23 pairs of chromosomes, giving a total of 46 chromosomes in each cell, called diploid cells. A normal sperm or egg cell contains only one half of these pairs and therefore 23 chromosomes. These cells are called haploid.
The euploid state describes when the number of chromosomes in each cell is some multiple of n, which may be 2n (46, diploid), 3n (69, triploid) 4n (92, tetraploid) and so on. When chromosomes are present in multiples beyond 4n, the term polyploid is used.
Aneuploidy refers to the presence of an extra chromosome or a missing chromosome and is the most common form of chromosomal abnormality. In the case of Down's syndrome or Trisomy 21, there is an additional copy of chromosome 21 and therefore 47 chromosomes. Turner's syndrome on the other hand arises from the absence of an X chromosome, meaning only 45 chromosomes are present.
Occasionally, aneuploid and regular diploid cells exist simultaneously and this is called mosaicism. The condition involves two or more different cell populations from a single fertilized egg. Mosaicism usually involves the sex chromosomes, although it can involve autosomal chromosomes.
In contrast to mosaicism, a condition called chimaerism occurs when different cell lines derived from more than one fertilized egg are involved.
Structural abnormalitiesStructural abnormalities occur when the chromosomal morphology is altered due to an unusual location of the centromere and therefore abnormal lengths of the chromosome's short (p) and long arm (q).
Some of the most common chromosomal abnormalities include:
Comments
Post a Comment